SynthesisFrontiers in immunology2026
Safety and efficacy of bispecific antibodies in hematologic neoplasms: a systematic review.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hematologic neoplasms remain a growing global burden, with relapse, resistance, and limited treatment options persisting. Bispecific antibodies (BsAbs) offer a novel multi-antigen targeting strategy. This systematic review assesses their efficacy and safety, offering an in-depth appraisal of their therapeutic potential and the unmet medical needs. Methods: We conducted this systematic review following the PRISMA 2020 guidelines. Articles published up to 20 June 2026 were searched across PubMed, Scopus, Web of Science, and Embase. Efficacy outcomes such as measurable residual disease (MRD), overall response rate (ORR), complete response (CR), overall survival (OS), and progression-free survival (PFS), as well as safety outcomes such as severe adverse events (SAEs), grade ≥3 adverse events (≥3 AEs), hematologic and non-hematologic toxicities were systematically evaluated. Results: Thirty-six studies evaluating nineteen different BsAbs were included. Blinatumomab (CD3-CD19) remains the most extensively studied bispecific antibody in relapsed or refractory B-cell precursor acute lymphoblastic leukemia (R/R BCP-ALL). CD3-CD20 BsAbs (Glofitamab, Epcoritamab) demonstrated durability in non-Hodgkin lymphoma (NHL). In multiple myeloma (MM), BCMA- and GPRC5D-targeting BsAbs achieved MRD negativity and deep responses including very good partial response (VGPR) and stringent complete response (sCR). BsAbs in acute myeloid leukemia (AML) and Hodgkin/T-cell lymphoma (HL/TCL) remained early-phase with limited efficacy and no approvals to date. Cytokine release syndrome (CRS) and neurotoxicity were the dominant toxicities of CD3-engaging agents (neurologic events >50% in several Blinatumomab studies). Teclistamab (CD3-BCMA) and Talquetamab (CD3-GPRC5D) were associated with frequent CRS, with neurotoxicity also reported. However, hematologic toxicity and infections remain major challenges in multiple myeloma treatment. Conclusion: BsAbs demonstrate established clinical activity in BCP-ALL, B-cell NHL, and MM but remain under investigation in AML, HL, and T-cell lymphoma. CRS, neurotoxicity, cytopenias, and infections remain key safety considerations. Further studies should optimize treatment strategies and evaluate emerging targets and non-CD3-engaging bispecific antibodies.The protocol was prospectively registered in PROSPERO (CRD42023467556). Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023467556.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.